{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:47:47Z","timestamp":1775123267954,"version":"3.50.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 69-year-old woman with breast cancer underwent <jats:sup>18<\/jats:sup>F-FDG PET\/CT because of the increased CA-15-3 level. <jats:sup>18<\/jats:sup>F-FDG PET\/CT showed multiple hypermetabolic lymph nodes (LNs) in the neck and mediastinum. The patient was also referred for <jats:sup>68<\/jats:sup>Ga\u2013fibroblast activation protein inhibitor (FAPI) 04 PET\/CT for further evaluation. However, <jats:sup>18<\/jats:sup>F-FDG\u2013avid LNs were FAPI-negative on <jats:sup>68<\/jats:sup>Ga-FAPI-04 PET\/CT. Supraclavicular LN biopsy confirmed the metastasis of breast cancer. Recent reports have focused on the potential of FAPI PET imaging in breast cancer; however, this case highlights that false-negative <jats:sup>68<\/jats:sup>Ga-FAPI-04-PET\/CT findings should also be considered while evaluating metastatic spread.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004704","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T19:02:44Z","timestamp":1684868564000},"page":"e380-e381","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["FAPI-Negative FDG-Avid Metastatic Relapse of Breast Cancer on PET\/CT"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4745-3501","authenticated-orcid":false,"given":"Caner","family":"Civan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duygu","family":"Has Simsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emine Goknur","family":"Isik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasemin","family":"Sanli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serkan","family":"Kuyumcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","year":"2021","journal-title":"Ann Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/RLU.0000000000003502","article-title":"Impact of 18F-FDG PET, PET\/CT, and PET\/MRI on staging and management as an initial staging modality in breast cancer: a systematic review and meta-analysis","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1053\/j.semnuclmed.2022.05.001","article-title":"FDG-PET\/CT for primary staging and detection of recurrence of breast cancer","volume":"52","year":"2022","journal-title":"Semin Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/MNM.0000000000000694","article-title":"Correlation of 18F-FDG PET\/CT with pathological features and survival in primary breast cancer","volume":"38","year":"2017","journal-title":"Nucl Med Commun"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"758958","DOI":"10.3389\/fonc.2021.758958","article-title":"Fibroblast-activated protein inhibitor PET\/CT: cancer diagnosis and management","volume":"11","year":"2021","journal-title":"Front Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/RLU.0000000000003667","article-title":"Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI04","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/RLU.0000000000003842","article-title":"Two tumors, one target: preliminary experience with 90Y-FAPI therapy in a patient with metastasized breast and colorectal cancer","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/RLU.0000000000004523","article-title":"68Ga-FAPI versus 18F-FDG PET\/CT in evaluating newly diagnosed breast cancer patients: a head-to-head comparative study","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/RLU.0000000000004505","article-title":"First clinical experience with [68Ga]Ga-FAPI-46-PET\/CT versus [18F]F-FDG PET\/CT for nodal staging in cervical cancer","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/RLU.0000000000004073","article-title":"Tumor imaging with 68Ga-DOTA-FAPI-04 PET\/CT: comparison with 18F-FDG PET\/CT in 22 different cancer types","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s12149-021-01616-5","article-title":"(68)Ga-FAPI-04 PET\/CT, a new step in breast cancer imaging: a comparative pilot study with the (18)F-FDG PET\/CT","volume":"35","year":"2021","journal-title":"Ann Nucl Med"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-021-05442-9","article-title":"(68)Ga-FAPI-04 vs. (18)F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer","volume":"49","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1007\/s00259-021-05453-6","article-title":"Both [(68)Ga]Ga-FAPI and [(18)F]FDG PET\/CT missed bone metastasis in a patient with breast cancer","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:06:33Z","timestamp":1750532793000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004704","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,23]]}}}